Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature

BMC Cancer. 2011 Jul 29:11:323. doi: 10.1186/1471-2407-11-323.

Abstract

Background: Primary leiomyosarcoma of the seminal vesicle is exceedingly rare.

Case presentation: We report a case of a 59-year-old man with tumour detected by rectal symptoms and ultrasonography. Computed tomography and magnetic resonance imaging suggested an origin in the right seminal vesicle. Transperineal biopsy of the tumour revealed leiomyosarcoma. A radical vesiculo-prostactectomy with bilateral pelvic lymphadenectomy was performed. Pathological examination showed a grade 2 leiomyosarcoma of the seminal vesicle. The patient received adjuvant radiotherapy. He developed distant metastases 29 months after diagnosis, and received chemotherapy. Metastatic disease was controlled by second-line gemcitabine-docetaxel combination. Fifty-one months after diagnosis of the primary tumour, and 22 months after the first metastases, the patient is alive with excellent performance status, and multiple asymptomatic stable lung and liver lesions.

Conclusions: We report the eighth case of primary leiomyosarcoma of the seminal vesicle and the first one with a so long follow-up.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Docetaxel
  • Gemcitabine
  • Genital Neoplasms, Male / diagnosis*
  • Genital Neoplasms, Male / therapy
  • Humans
  • Leiomyosarcoma / diagnosis*
  • Leiomyosarcoma / therapy
  • Liver Neoplasms / prevention & control
  • Liver Neoplasms / secondary
  • Lung Neoplasms / prevention & control
  • Lung Neoplasms / secondary
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Prostatectomy
  • Radiotherapy, Adjuvant
  • Seminal Vesicles / pathology*
  • Taxoids / administration & dosage
  • Treatment Outcome

Substances

  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • Gemcitabine